Want to see IRMD full AI Analyst Report?
IRMD Stock Chart & Stats
$94.49
$0.59(0.62%)
At close: 4:00 PM EDT
$94.49
$0.59(0.62%)
Day’s Range― - ―
52-Week Range$67.51 - $107.90
Previous Close$95.08
Volume67.19K
Average Volume (3M)128.61K
Market Cap
$1.16B
Enterprise Value$1.17K
Total Cash (Recent Filing)$59.08M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)50.2
Beta0.64
Next Earnings
Oct 29, 2026EPS Estimate
0.55Next Dividend Ex-DateN/A
Dividend Yield1.36%
Share Statistics
EPS (TTM)1.82
Shares Outstanding12,783,035
10 Day Avg. Volume112,129
30 Day Avg. Volume128,611
Financial Highlights & Ratios
PEG Ratio3.34
Price to Book (P/B)13.08
Price to Sales (P/S)14.77
P/FCF Ratio72.03
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$120.00Price Target Upside27.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)2.08
Revenue Forecast (FY)$91.20M
Bulls Say, Bears Say
Bulls Say
High Gross And Net MarginsIRADIMED’s consistently very high gross (≈76%) and net (~27%) margins reflect a differentiated, high-ASP product portfolio and strong pricing power in MRI-compatible devices. Durable margins support internal funding of R&D, dividends and growth initiatives, insulating profitability through normal capital-cycle variability.
Debt-free Conservative Balance SheetA near-zero debt profile and strong ROE provide financial flexibility to fund product ramps, working capital and buybacks/dividends without refinancing risk. This lowers bankruptcy risk, supports steady investment in manufacturing scale and cushions the company versus hospital capital spending cycles.
Expanding Recurring Revenue From Consumables & ServicesIncreasing disposables, maintenance amortization and service revenue signal a growing installed base and more predictable, higher-margin recurring streams. This structural shift improves revenue visibility, raises lifetime customer value, and stabilizes cash flow beyond episodic capital-equipment sales.
Bears Say
Ramp-related Margin CompressionInitial 3870 production inefficiencies materially compressed margins in Q2. If scale-up or learning-curve gains are slower than planned, elevated manufacturing overhead and start-up labor can persist, eroding the company’s strong margin profile and reducing free cash flow until efficiencies are realized.
Slowing Top-line GrowthRevenue growth has decelerated to low single digits on a trailing basis, reducing operational leverage on fixed costs and increasing sensitivity to execution. Sustained slower growth would force higher reliance on ASP uplifts and consumables to meet profit expansion targets and could magnify the impact of any market headwinds.
Execution Risk From Aggressive Production RampManagement’s plan to more than double production quickly concentrates downside risk in manufacturing, supply chain and labor. Missed targets or persistent overtime/inefficiencies would prolong margin drag, delay revenue recognition from backlog and could increase warranty or quality costs tied to a hurried scale-up.
Iradimed News
IRMD FAQ
What was Iradimed Corp’s price range in the past 12 months?
Iradimed Corp lowest stock price was $67.51 and its highest was $107.90 in the past 12 months.
What is Iradimed Corp’s market cap?
Iradimed Corp’s market cap is $1.16B.
When is Iradimed Corp’s upcoming earnings report date?
Iradimed Corp’s upcoming earnings report date is Oct 29, 2026 which is in 85 days.
How were Iradimed Corp’s earnings last quarter?
Iradimed Corp released its earnings results on Jul 31, 2026. The company reported $0.46 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.02.
Is Iradimed Corp overvalued?
According to Wall Street analysts Iradimed Corp’s price is currently Undervalued.
Does Iradimed Corp pay dividends?
Iradimed Corp pays a Quarterly dividend of $0.2 which represents an annual dividend yield of 1.36%. See more information on Iradimed Corp dividends here
What is Iradimed Corp’s EPS estimate?
Iradimed Corp’s EPS estimate is 0.55.
How many shares outstanding does Iradimed Corp have?
Iradimed Corp has 12,783,035 shares outstanding.
What happened to Iradimed Corp’s price movement after its last earnings report?
Iradimed Corp reported an EPS of $0.46 in its last earnings report, beating expectations of $0.44. Following the earnings report the stock price went down -4.569%.
Which hedge fund is a major shareholder of Iradimed Corp?
Currently, no hedge funds are holding shares in IRMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Iradimed Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$120.00 (27.00% Upside)
$120.00 (27.00% Upside)
Blogger Sentiment
Neutral
IRMD Sentiment 50%
Sector Average 65%
Sector Average 65%
Hedge Fund Trend
Decreased
By 11.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $285.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 7.1%
Last 30 Days ▼ 7.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
69.27%
12-Months-Change
Fundamentals
Return on Equity
1.36%
Trailing 12-Months
Asset Growth
8.01%
Trailing 12-Months
Company Description
Iradimed Corp
IRADIMED CORPORATION specializes in the engineering, production, and distribution of medical devices specifically designed for compatibility with magnetic resonance imaging (MRI) environments. The company supplies these specialized products, alongside their related accessories and support services, to both U.S. and international markets. Key offerings include the MRidium MRI-compatible intravenous (IV) infusion pump system, which comes with disposable tubing sets, and an MRI-compatible patient vital signs monitoring system. Furthermore, IRADIMED provides a range of complementary items such as non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring solutions with sensors. Their clientele primarily consists of hospitals, acute care facilities, and outpatient imaging centers. Sales are conducted via direct field representatives, regional sales directors, clinical support specialists, and independent distributors. Founded in 1992, IRADIMED CORPORATION is headquartered in Winter Springs, Florida.
IRMD Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a largely positive outlook driven by a successful product launch (3870 pump), strong bookings (bookings >2x units shipped), higher ASPs from quad replacements, record monitor orders, and improving recurring revenue and cash flows. Near-term challenges include margin compression and higher costs from the initial production ramp, a modest decline in quarterly net income and gross margin, and an elevated effective tax rate. Management provided clear plans and guidance to double down on ramp execution, expects significant cost reductions in Q3 and near-historic efficiencies by Q4, and reaffirmed full-year guidance — resulting in confidence that the positive drivers outweigh the near-term operational headwinds.View all IRMD earnings summariesIRMD Stock 12 Month Forecast
Average Price Target
$120.00
▲(27.00% Upside)
Technical Analysis
Ownership Overview
34.87% Insiders
12.95% Mutual Funds
4.85% Other Institutional Investors
37.77% Public Companies and
Individual Investors